pegvisomant: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
pegvisomant: clinical details
Prescribing considerations
- Initiate under an endocrinologist experienced in managing acromegaly.
- Record the product name and batch number for biological-medicine traceability.
- Assess baseline liver tests and investigate significant abnormalities or possible biliary obstruction before treatment.
- Review insulin or other glucose-lowering therapy because insulin sensitivity may improve.
- Safety and efficacy have not been established in children or in hepatic or renal insufficiency.
Contraindications and cautions
- Hypersensitivity to pegvisomant or any listed excipient.
- Use during pregnancy or breastfeeding is not recommended; specialist risk–benefit review is required if relevant.
Monitoring
- Use age-adjusted serum IGF-I to assess response; growth hormone assays are unsuitable because pegvisomant cross-reacts and can produce misleading results.
- Monitor liver function at baseline and during treatment, with prompt investigation of biochemical abnormalities or symptoms of liver injury.
- Monitor pituitary tumour size and assess new headache or visual-field symptoms.
- Monitor glucose closely in patients receiving insulin or other glucose-lowering treatment.
- Inspect injection sites for reactions or lipohypertrophy.
Clinical pharmacology
Pegvisomant selectively antagonises cell-surface growth hormone receptors, reducing downstream signalling and serum IGF-I. Subcutaneous absorption and elimination are prolonged, while renal clearance is negligible.
Formulation and product differences
- The selected product is a single-use powder vial supplied with water for injections in a pre-filled syringe and a safety needle.
- The reconstituted solution must not be mixed with other medicines and should be used immediately.
- The powder requires refrigerated, light-protected storage, with a permitted single room-temperature storage period under the conditions stated in the product information; it must not be returned to the refrigerator afterwards.
pegvisomant preparations and strengths
Injection
Route: Parenteral
Strengths: 10 mg, 15 mg, 20 mg, 25 mg, 30 mg
pegvisomant interactions
Formal interaction studies are limited. Important practical considerations include:
Insulin and other glucose-lowering medicines
Pegvisomant can improve insulin sensitivity, increasing the risk of low blood glucose; glucose monitoring and treatment review may be needed.
Somatostatin analogues and other acromegaly treatments
Combination use has not been extensively investigated, so the specialist should decide whether existing treatment continues.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.